Withdrawn cancer trial leaves questions unanswered
NCT ID NCT05312372
Summary
This early-stage trial aimed to test the safety and initial effectiveness of a new drug called S095033 when combined with standard chemotherapy (paclitaxel) for people with advanced esophageal cancer that had stopped responding to previous treatments. The study was designed to find the right dose and see if the combination could help control tumor growth. However, the trial was withdrawn before any patients were enrolled, so no results are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.